Financial Reports Latest Updates Industry Maps Economic Calendar

Voyager Therapeutics, Inc. (VYGR) Annual Reports

Q: Where can I read Voyager Therapeutics, Inc. (VYGR) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Voyager Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Biological Products, (No Diagnostic Substances) (SIC 2836). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1640266 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$3.2M	$5.2M	-39.1%
Operating income	$-26.4M	$-36.6M	+27.9%
Net income	$-24.5M	$-33.4M	+26.7%
EPS (diluted)	$-0.40	$-0.57	+29.8%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 3.17 mn Net income -24.5 mn

Show table：Income statement

Item	2014Q1	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	2.58	4.88	4.94	4.94	4.83	3.72	3.31	2.36	1.46	1.18	1.15	6.35	0.94	2.58	2.09	2.01	5.20	46.1	20.4	32.7	18.1	28.7	118	6.54	6.50	1.36	1.48	28.1	0.66	0.71	41.1	-1.55	150	4.85	4.61	90.1	19.5	29.6	24.6	6.28	6.47	5.20	13.4	15.3	2.59	3.17
Operating income	-3.77	-3.66	-4.50	-4.83	-3.97	-4.02	-7.44	-7.47	-9.62	-10.4	-13.8	-17.5	-18.6	-23.4	-12.3	-21.1	-25.7	-21.1	-23.2	-29.3	9.19	-17.8	-13.8	-24.4	-8.98	84.5	-23.7	-25.6	-28.6	-25.1	5.70	-21.4	-19.4	14.4	-24.6	123	-25.4	-29.5	54.1	-16.2	-15.0	-13.8	-38.3	-34.7	-36.6	-30.6	-29.9	-30.3	-26.4
Net income	-3.83	-4.00	-4.69	-14.6	-3.89	-3.92	-7.28	-7.19	-9.34	-9.00	-14.7	-16.6	-18.9	-23.4	-11.8	-19.9	-25.5	-20.3	-22.5	-27.2	11.2	-15.0	-12.6	-24.3	-8.68	85.6	-15.9	-21.6	-30.1	-25.1	5.71	-21.3	-19.1	17.6	-23.6	124	-22.2	-25.9	56.4	-11.3	-10.1	-9.04	-34.5	-31.0	-33.4	-27.9	-27.4	-27.9	-24.5

Balance sheet

Quarterly · In mn (USD)

Total assets 198 mn Total liabilities 43.4 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014Q1	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	8.36	—	—	109	196	206	205	193	179	161	145	128	172	221	200	182	162	365	341	328	305	272	247	216	198	176	149	126	137	171	152	147	125	303	282	262	320	409	382	373	277	245	228	220	203	147	125
Total assets	—	—	11.5	—	—	166	229	220	210	202	190	175	158	141	184	235	215	197	177	411	389	376	355	323	297	270	262	238	209	185	194	224	189	182	159	336	316	295	351	470	436	426	393	353	322	288	252	219	198
Current liabilities	—	—	2.47	—	—	23.4	23.9	23.1	19.8	19.4	13.8	11.1	11.8	20.9	15.9	30.9	29.1	30.0	31.7	58.8	69.2	80.2	76.0	72.5	67.5	42.0	26.8	24.8	24.7	26.7	51.0	102	97.9	73.2	72.6	19.9	45.4	61.7	64.5	72.5	40.1	44.2	49.8	40.2	42.0	35.5	26.5	17.4	16.7
Total liabilities	—	—	10.3	—	—	64.7	60.4	56.4	54.1	52.9	53.6	52.4	53.1	55.7	50.4	137	133	131	131	311	270	268	255	243	221	104	107	102	98.2	97.3	98.8	148	129	103	100	119	117	118	115	129	101	95.7	93.3	80.5	78.2	68.5	56.2	45.7	43.4
Equity	-3.83	—	-20.8	—	—	-47.1	169	164	156	149	136	123	105	85.2	134	98.3	82.0	65.6	46.5	101	118	108	99.5	79.8	76.9	166	154	136	111	87.4	95.1	75.9	60.0	79.8	59.0	217	199	176	236	341	335	330	300	273	244	220	196	174	154

Cash flow

Quarterly · In mn (USD)

Operating -25.8 mn Investing 15.4 mn Financing 2.91 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014Q1	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-2.72	-7.13	-4.79	64.6	-6.98	-6.75	-9.56	-9.49	-9.71	-10.2	-13.1	-14.3	-16.3	-15.9	-14.8	48.6	-22.5	-17.6	-24.4	125	-31.6	-21.6	-23.4	-28.8	-21.2	-24.7	-22.0	-21.3	-22.7	-20.7	11.2	34.4	-18.5	-16.2	-12.2	124	-0.83	-21.1	-23.8	58.8	-31.6	-28.0	-14.5	-37.9	-33.3	-31.1	-30.3	-33.4	-25.8
Investing	—	-2.29	-1.01	-0.15	-84.5	-10.5	-99.6	12.1	42.8	6.61	-14.1	20.7	38.5	-2.77	-60.1	58.4	-59.4	-1.19	28.6	-137	-2.89	22.6	26.5	109	-1.84	27.4	-21.5	34.6	22.4	14.3	-5.46	-20.0	-36.1	34.7	14.1	14.5	-24.7	-158	26.8	-96.1	-35.9	64.3	-27.2	41.2	1.93	34.9	47.4	8.10	15.4
Financing	2.86	15.6	6.51	44.9	59.9	-0.95	73.9	0	0.09	0.05	0.37	0.6	0.5	0.56	58.3	1.83	1.12	1.37	0.44	77.9	1.07	1.72	0.3	0.03	2.13	0.51	0.49	0.03	0.36	0	0.23	0.01	0.81	0.02	0.28	31.3	1.55	0.33	0.46	113	0.57	0.01	0.57	0.08	0.51	0.09	0.14	3.33	2.91
Cash at period end	0.14	6.33	7.04	116	84.8	66.5	31.3	33.9	67.0	63.5	36.6	43.6	66.3	48.2	31.5	140	59.6	42.1	46.9	113	79.9	82.6	86.0	165	144	147	104	118	118	111	117	132	78.3	96.9	99.0	268	244	65.3	68.8	143	76.1	113	71.4	74.8	43.9	45.1	65.3	43.3	35.8

Profitability

Quarterly · %

Operating margin -833.9% Net margin -773.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2014Q1	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	-187.4%	-81.2%	-81.4%	-150.7%	-154.6%	-258.6%	-313.5%	-586.1%	-1196.9%	-1583.6%	-2034.4%	-194.6%	-2239.2%	-997.8%	-1009.9%	-1153.4%	-563.6%	19.9%	-87.2%	-42.1%	-135.2%	-31.3%	71.7%	-363.0%	-393.6%	-2106.5%	-1696.8%	20.3%	-3244.7%	-2720.1%	35.1%	—	81.7%	-523.9%	-639.5%	60.0%	-82.9%	-50.8%	-56.0%	-610.0%	-536.0%	-704.3%	-228.9%	-195.2%	-1167.4%	-833.9%
Net margin	—	—	—	-565.9%	-79.8%	-79.3%	-147.5%	-148.8%	-250.9%	-271.9%	-621.2%	-1137.2%	-1603.7%	-2033.6%	-186.4%	-2115.3%	-991.9%	-968.9%	-1122.1%	-522.8%	24.2%	-73.4%	-38.5%	-134.3%	-30.3%	72.7%	-243.6%	-333.0%	-2219.6%	-1696.2%	20.3%	-3240.0%	-2680.8%	42.9%	—	82.4%	-457.6%	-561.4%	62.6%	-58.0%	-34.3%	-36.7%	-549.3%	-479.2%	-642.0%	-208.7%	-178.8%	-1077.4%	-773.2%

Returns & leverage

Quarterly · %

ROE -54.1% ROA -41.5% Debt ratio 21.9%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2014Q1	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	-40.0%	-13.6%	-17.8%	-64.3%	-26.4%	-34.7%	-45.4%	-62.8%	-52.4%	-67.0%	-86.1%	-102.9%	-97.8%	-96.0%	-58.7%	-61.6%	-59.7%	-45.1%	-62.0%	29.2%	28.9%	36.5%	19.1%	-73.2%	-57.1%	-66.8%	-70.2%	-20.4%	-60.2%	67.6%	74.0%	40.9%	89.6%	-1.1%	3.4%	10.2%	-24.3%	-27.6%	-37.3%	-46.1%	-48.3%	-52.3%	-54.1%
ROA	—	—	—	—	—	-16.3%	-24.6%	-10.1%	-13.2%	-17.8%	-19.2%	-25.1%	-32.1%	-42.9%	-37.8%	-36.1%	-43.2%	-45.9%	-48.8%	-29.6%	-19.5%	-18.7%	-16.4%	-11.1%	-17.6%	12.4%	11.9%	14.1%	7.1%	-40.9%	-31.3%	-30.7%	-30.1%	-9.3%	-26.3%	35.3%	38.0%	21.9%	51.8%	-0.8%	2.4%	7.2%	-17.5%	-20.6%	-28.5%	-35.5%	-37.1%	-40.7%	-41.5%
Debt ratio	—	—	90.0%	—	—	38.9%	26.3%	25.6%	25.8%	26.2%	28.3%	29.9%	33.5%	39.5%	27.3%	58.2%	61.8%	66.7%	73.8%	75.5%	69.5%	71.3%	72.0%	75.3%	74.2%	38.4%	41.0%	42.7%	47.0%	52.7%	51.0%	66.1%	68.2%	56.3%	63.0%	35.5%	36.9%	40.2%	32.7%	27.4%	23.1%	22.5%	23.7%	22.8%	24.3%	23.8%	22.3%	20.8%	21.9%

EPS

Quarterly · US$

EPS US$-0.40

Show table：EPS

Item	2014Q1	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.80	—	-1.32	—	0.29	-0.41	-0.34	—	-0.23	2.27	-0.42	-0.58	-0.80	-0.67	0.15	-0.56	-0.50	0.45	-0.62	2.94	-0.51	-0.59	1.19	-0.20	-0.18	-0.16	-0.60	-0.53	-0.57	-0.47	-0.47	-0.47	-0.40

Revenue & profit

Year-to-date · In mn (USD)

Revenue 5.76 mn Net income -52.4 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 198 mn Total liabilities 43.4 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -59.3 mn Investing 23.5 mn Financing 6.24 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -984.1% Net margin -910.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -54.1% ROA -41.5% Debt ratio 21.9%

EPS

Year-to-date · US$

EPS US$-0.87

Revenue & profit

Annual · In mn (USD)

Revenue 40.4 mn Net income -120 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	17.3	14.2	10.1	7.62	104	171	37.4	40.9	250	80.0	40.4
Operating income	-20.3	-41.3	-71.9	-91.1	-51.7	27.4	-73.6	-50.8	122	-83.3	-132
Net income	-29.7	-40.2	-70.7	-88.3	-43.6	36.7	-71.2	-46.4	132	-65.0	-120

Balance sheet

Annual · In mn (USD)

Total assets 252 mn Total liabilities 56.2 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	196	179	172	162	305	198	137	125	320	277	203
Total assets	229	190	184	177	355	262	194	159	351	393	252
Current liabilities	23.9	13.8	15.9	31.7	76.0	26.8	51.0	72.6	64.5	49.8	26.5
Total liabilities	60.4	53.6	50.4	131	255	107	98.8	100	115	93.3	56.2
Equity	169	136	134	46.5	99.5	154	95.1	59.0	236	300	196

Cash flow

Annual · In mn (USD)

Operating -132 mn Investing 125 mn Financing 0.82 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	41.3	-42.5	-61.4	-15.9	48.7	-96.7	-53.5	-12.5	77.9	-15.3	-132
Investing	-195	47.3	-3.68	26.5	-90.5	113	65.9	-7.34	-142	-94.9	125
Financing	178	0.51	59.9	4.75	81.0	3.16	0.61	1.11	33.6	114	0.82
Cash at period end	31.3	36.6	31.5	46.9	86.0	104	117	99.0	68.8	71.4	65.3

Profitability

Annual · %

Operating margin -326.6% Net margin -296.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	-116.8%	-290.4%	-709.1%	-1195.6%	-49.5%	16.0%	-196.8%	-124.3%	48.8%	-104.1%	-326.6%
Net margin	-171.2%	-282.6%	-697.6%	-1158.8%	-41.8%	21.5%	-190.3%	-113.5%	52.9%	-81.3%	-296.5%

Returns & leverage

Annual · %

ROE -48.3% ROA -37.1% Debt ratio 22.3%

Show table：Returns & leverage

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-17.6%	-26.4%	-52.4%	-97.8%	-59.7%	28.9%	-57.1%	-60.2%	89.6%	-24.3%	-48.3%
ROA	-12.9%	-19.2%	-37.8%	-48.8%	-16.4%	11.9%	-31.3%	-26.3%	51.8%	-17.5%	-37.1%
Debt ratio	26.3%	28.3%	27.3%	73.8%	72.0%	41.0%	51.0%	63.0%	32.7%	23.7%	22.3%

EPS

Annual · US$

EPS US$-2.04

Show table：EPS

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	-1.90	-1.23	3.03	-1.14	-2.04

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Voyager Therapeutics, Inc. (VYGR) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.